Day One

Settle in with morning refreshments while enjoying early, informal access to your peers and identify

who you’d like to engage with further across the next two days of the event.

• Discussing the European Obesity Landscape to accelerate innovation
• Explore the most promising innovations beyond first-generation obesity therapeutics to guide future pipelines and strategic investment decisions
• Address the real-world challenges of infrastructure and adoption to expand patient access and commercial reach across Europe

• Highlighting an attractive GLP1-independent drug discovery approach
• Profiling potent peptide agonists for convenient weight loss
• Combining complementary MoAs for well tolerated and effective anti-obesity therapy

As the community unites, this session will provide valuable networking time with your peers,

enabling you to forge new and lasting connections.

• Analysing the GIP pathway to identify opportunities to leverage GIP antagonism for diabetes treatments as a comorbidity of obesity
• Highlighting data showcasing robust effects in type 2 diabetes and insulin sensitivity improvement when GIP is combined with GLP-1 to expand indication treatment opportunities

• Introducing APN-EV, the first stable, functional multimeric adiponectin, to improve insulin sensitivity and drive fat clearance
• Demonstrating synergistic fat loss with microdose APN-EV and GLP-1R agonists to enhance efficacy while preserving muscle mass and address the sarcopenia challenges associated with incretin-based therapies
• Exploring the translational and commercial potential of the EV platform, including manufacturing scalability, cost-of-goods advantages

Enjoy lunch as you spark new discussions and build relationships that can drive impact

• Exploring a non-food intake reducing approach to combat gastrointestinal side effects
• Delving into the mechanistic insights of targeting adipose tissue to highlight efficacy benefits
• Focusing on energy expenditure in a novel and safe way to reduce comorbidities

• Highlighting mode of actions to increase energy expenditure
• Targeting bioenergetics for safe and tolerable increase in energy expenditure to treat metabolic diseases
• Determining which tissue to target to ensure enough efficacy for different therapeutic areas

• Developing a differentiated mode of action from appetite suppression to generate as good efficacy of dual incretins
• Restoring mitochondrial function with a new mode of action to target obesity
• Targeting energy expenditure form switching to carbohydrate
• Exploring metabolic and obesity drivers

This is your opportunity to contribute to the conversation and share your cutting-edge research with the community while discovering exciting work carried out by your peers. To submit a poster, please contact info@hansonwade.com.

• Comparing modality trade-offs in potency, safety and half-life between oral small molecules and injectable peptide therapeutics to guide smarter development decisions
• Exploring how advances in oral delivery and next-generation formats to expand treatment options beyond injectables
• Discussing the manufacturing strengths and pitfalls of oral, DNA and injectable peptide therapies to align delivery mechanisms with commercial viability and faster routes to market

• Evaluating the key challenges of maintaining a robust and efficient supply chain to identify strategies to meet the increased demand of weight loss therapeutics
• Exploring opportunities to decrease peptide manufacturing complexity to reduce COGs and allow seamless commercial scale up
• Highlighting manufacturing and development innovation to expanding patient access and secure long-term commercial viability
• Utilising biological processes to decrease solvent use and enhance sustainable drug development